“…In response to this charge, public and private institutions in the United States have invested billions of dollars since the early 2000s to maximize the interaction between treatment characteristics (e.g., type, dosage, setting) and desired therapeutic response through clinical trials (Institute of Medicine, 2014). Consequently, scientist‐practitioners developed a number of therapeutic strategies intended to mitigate the symptoms of PTSD (Cohen, Mannarino, & Deblinger, 2017; Foa, Hembree, & Rothbaum, 2007; Monson & Shnaider, 2014; Resick, Monson, & Chard, 2017; Shapiro, 2001) that were identified as efficacious across primary studies and within meta‐analyses (Erford et al, 2016; Lenz, Haktanir, & Callender, 2017). As a result, individuals experiencing PTSD have access to more sophisticated therapeutic interventions than ever before, with considerable fiduciary implications for individual consumers, third‐party payers, and government entities that compensate providers of evidence‐based practices.…”